Mark J Selby
Overview
Explore the profile of Mark J Selby including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
1381
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lopez-Bujanda Z, Haffner M, Chaimowitz M, Chowdhury N, Venturini N, Patel R, et al.
Nat Cancer
. 2022 Feb;
2(8):803-818.
PMID: 35122025
Unlike several other tumor types, prostate cancer rarely responds to immune checkpoint blockade (ICB). To define tumor cell intrinsic factors that contribute to prostate cancer progression and resistance to ICB,...
2.
Freeman Z, Nirschl T, Hovelson D, Johnston R, Engelhardt J, Selby M, et al.
J Clin Invest
. 2020 Feb;
130(3):1405-1416.
PMID: 32015231
Despite advancements in targeting the immune checkpoints program cell death protein 1 (PD-1), programmed death ligand 1 (PD-L1), and cytotoxic T lymphocyte-associated protein 4 (CTLA-4) for cancer immunotherapy, a large...
3.
Aryl hydrocarbon receptor acts as a tumor suppressor in a syngeneic MC38 colon carcinoma tumor model
Yakkundi P, Gonsalves E, Galou-Lameyer M, Selby M, Chan W
Hypoxia (Auckl)
. 2019 May;
7:1-16.
PMID: 31119183
Aryl hydrocarbon receptor (AHR), commonly known as an environmental sensor involved in the metabolism and elimination of xenobiotic substances, is also an important modulator in the development and functioning of...
4.
Marciscano A, Ghasemzadeh A, Nirschl T, Theodros D, Kochel C, Francica B, et al.
Clin Cancer Res
. 2018 Jun;
24(20):5058-5071.
PMID: 29898992
In the proper context, radiotherapy can promote antitumor immunity. It is unknown if elective nodal irradiation (ENI), a strategy that irradiates tumor-associated draining lymph nodes (DLN), affects adaptive immune responses...
5.
Lewis K, Selby M, Masters G, Valle J, Dito G, Curtis W, et al.
Oncoimmunology
. 2018 Jan;
7(1):e1377873.
PMID: 29296539
Recent advances in cancer treatment with checkpoint blockade of receptors such as CTLA-4 and PD-1 have demonstrated that combinations of agents with complementary immunomodulatory effects have the potential to enhance...
6.
Shen Y, Ghasemzadeh A, Kochel C, Nirschl T, Francica B, Lopez-Bujanda Z, et al.
Prostate Cancer Prostatic Dis
. 2017 Dec;
21(1):113-125.
PMID: 29203894
Background: Immune checkpoint blockade has shown promising antitumor activity against a variety of tumor types. However, responses in castration-resistant prostate cancer remain relatively rare-potentially due to low baseline levels of...
7.
Noguchi T, Ward J, Gubin M, Arthur C, Lee S, Hundal J, et al.
Cancer Immunol Res
. 2017 Jan;
5(2):106-117.
PMID: 28073774
Antibody blockade of programmed death-1 (PD-1) or its ligand, PD-L1, has led to unprecedented therapeutic responses in certain tumor-bearing individuals, but PD-L1 expression's prognostic value in stratifying cancer patients for...
8.
Selby M, Engelhardt J, Johnston R, Lu L, Han M, Thudium K, et al.
PLoS One
. 2016 Nov;
11(11):e0167251.
PMID: 27861630
[This corrects the article DOI: 10.1371/journal.pone.0161779.].
9.
Selby M, Engelhardt J, Johnston R, Lu L, Han M, Thudium K, et al.
PLoS One
. 2016 Sep;
11(9):e0161779.
PMID: 27610613
The monoclonal antibodies ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1) have shown remarkable antitumor activity in an increasing number of cancers. When combined, ipilimumab and nivolumab have demonstrated superior activity in patients...
10.
Wang C, Thudium K, Han M, Wang X, Huang H, Feingersh D, et al.
Cancer Immunol Res
. 2014 May;
2(9):846-56.
PMID: 24872026
The programmed death-1 (PD-1) receptor serves as an immunologic checkpoint, limiting bystander tissue damage and preventing the development of autoimmunity during inflammatory responses. PD-1 is expressed by activated T cells...